Tag Archives: INHBE

Innovent Initiates Ph1 INHBE China-based Study in Obesity; BioLife Receives Patent for Dissolvable Obesity Medicine; Novo’s Semaglutide Approved for MASH in China

Three cardiometabolic-related news items have been observed: Innovent Biologics initiated a Ph1 FIH study of its Q3M/Q6M SC INHBE (view CT.gov record); BioLife received a US patent for its effervescent oral peptide delivery technology (view press release); and Novo Nordisk’s injectable semaglutide received approval from NMPA for the treatment of F2-F3 MASH (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Viking Ph1 DACRA Study; Lilly Collaborates with Oura; Pivot Patch Pump US Launch; Wave Initiates Ph2a MAD INLIGHT Study; Wegovy FlexTouch Label Update; Tryngolza sHTG US Approval

A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Lilly/Oura, Modular Medical, Wave Life Sciences, Novo Nordisk, and Ionis Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Ionis, Wave, and MannKind Q4 ’25 Earnings; New Ph2 Olatorepatide Study; ACHIEVE-3 Full Results; MindRank Doses First Patient in Ph3 Oral GLP-1RA Study; Fractyl Completes Pivotal Enrollment

A series of cardiometabolic-related news items has been observed from Ionis Pharmaceuticals, Wave Life Sciences, Regeneron, Lilly, MannKind, MindRank, and Fractyl Health. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here